TMAO: When to Order This Test and What the Results Mean

The direct answer

TMAO testing has a narrow, defensible clinical role: it adds information in patients whose cardiovascular risk is not fully explained by LDL cholesterol, blood pressure, and other standard markers, particularly those with recurrent cardiac events, chronic kidney disease, or a high-choline diet. The seminal cohort study linking TMAO to cardiovascular outcomes, published in the New England Journal of Medicine, found that higher plasma TMAO was associated with increased risk of major adverse cardiovascular events independent of traditional risk factors (Tang et al., NEJM 2013). That finding is observational, not a treatment trial. It tells you TMAO is a risk marker; it does not tell you that lowering TMAO prevents heart attacks, because no outcome trial of a TMAO-lowering intervention has reported that result.

What TMAO is, and what it is not

TMAO is not a drug, a supplement, or a peptide. It is an endogenous metabolite the body produces from food. Gut bacteria convert dietary choline, phosphatidylcholine, L-carnitine, and betaine into trimethylamine (TMA), which travels through the portal circulation to the liver, where the enzyme flavin monooxygenase 3 (FMO3) oxidizes it into TMAO. Levels depend on three things: what a person eats, which bacterial species are present in their gut, and how well their kidneys clear TMAO from blood. This is why TMAO should be interpreted alongside diet history and renal function rather than as a stand-alone number.

When ordering TMAO is reasonable

TMAO is not part of routine lipid or metabolic screening panels. Ordering it is most defensible in a small number of situations where the standard risk picture is incomplete.

Recurrent or unexplained cardiovascular events. Patients who have a heart attack, stroke, or unstable angina despite controlled LDL and blood pressure are the group in whom TMAO has the clearest rationale, since the original outcome data come from exactly this kind of population. A cohort study in stable coronary artery disease patients, published in the Journal of the American Heart Association, reported that higher TMAO was associated with increased long-term mortality risk independent of traditional risk factors (Senthong et al., JAHA). The exact magnitude of that association should be confirmed against the primary paper before being quoted to a patient; the direction of the finding (higher TMAO, higher risk in this population) is the more durable takeaway.

Chronic kidney disease. TMAO is cleared by the kidneys, so it accumulates as glomerular filtration rate falls. In patients with CKD, elevated TMAO has been reported to track with worse outcomes in cohort studies. Because CKD itself raises TMAO through reduced clearance rather than increased production, a high TMAO value in a CKD patient reflects kidney function at least as much as diet or microbiome, and should not be read as an independent new risk factor without accounting for eGFR.

High red meat, egg, or carnitine-supplement intake with borderline cardiovascular risk. Diet is the largest modifiable input into TMAO. Feeding studies have shown that a red-meat-heavy diet raises plasma TMAO compared with white meat or plant protein, and that switching away from red meat lowers it within weeks. The size of that effect varies across studies and should be treated as a directional finding rather than a fixed percentage.

Intermediate cardiovascular risk with a strong family history of early disease. In a patient whose calculated risk score is ambiguous, TMAO is sometimes used as one of several adjunct markers alongside things like coronary calcium scoring, in line with the general principle that adjunct biomarkers can help refine risk in intermediate-risk patients. This use is a matter of clinical judgment rather than a specific guideline mandate, and readers should not assume a named professional society has issued a TMAO-specific recommendation; that claim requires direct verification against the current guideline text before being repeated in a chart note.

Post-bariatric surgery, as a research-informed observation. Gut microbiome composition changes substantially after Roux-en-Y gastric bypass or sleeve gastrectomy, and TMAO shifts in some patients but not others. This is a plausible but incompletely characterized area; a specific responder rate should not be treated as established without checking the primary study.

Who does not need this test

TMAO adds little value in patients already on optimal medical therapy with controlled risk factors and no unexplained events, since a result is unlikely to change management. Reference ranges for children and adolescents are not established. Anyone who recently completed a broad-spectrum antibiotic course will likely have an artificially suppressed TMAO for a period of weeks, because antibiotics disrupt the TMA-producing gut bacteria the test depends on; testing during or shortly after antibiotics is not reliable. Most insurance plans do not cover TMAO for primary prevention screening (as of 2026), so the out-of-pocket cost is worth weighing against how much the result will actually change the plan of care.

How to read the number

Commercial laboratories commonly describe fasting plasma TMAO below roughly 6.2 µmol/L as low cardiovascular risk, a moderate zone in the high single digits, and values at or above about 10 µmol/L as higher risk. These cutpoints come from population outcome studies at specific reference laboratories rather than from a single cross-society consensus guideline, and different labs report different reference ranges. Treat the number as a risk gradient rather than a diagnostic threshold with a sharp cutoff.

Elevated TMAO signals more gut-derived pro-atherogenic and pro-thrombotic activity. Mechanistic studies, including work published in Cell, have shown that TMAO can enhance platelet responsiveness and promote macrophage foam cell formation in vitro and in animal models (Zhu et al., Cell). That is mechanistic and preclinical evidence explaining a plausible biological pathway; it is not proof that lowering TMAO in a person will reduce their clotting risk. A high TMAO result means the patient has a modifiable metabolic risk factor worth discussing, not that an event is imminent.

Low TMAO (generally under about 2 µmol/L) is not a concern. It usually reflects a diet lower in animal-derived choline and carnitine, a gut microbiome that produces less TMA, or efficient kidney clearance. There is no recognized clinical condition caused by TMAO being too low, and no treatment is indicated to raise it.

Things that distort the result. Recent deep-sea or saltwater fish intake can spike TMAO because marine fish already contain preformed TMAO in their tissue, separate from the gut-bacterial pathway; a short washout before testing (roughly 48 hours off seafood) reduces this confound. Recent antibiotic use suppresses TMAO. Reduced kidney function raises TMAO through impaired clearance rather than increased production. Any of these should be considered before treating a single value as a stable baseline.

What lowering TMAO can and cannot promise

TMAO responds to intervention faster than most cardiovascular risk markers, which is part of why it draws interest. Reducing red meat intake lowers plasma TMAO within weeks in feeding studies, and Mediterranean-style dietary patterns are associated with lower TMAO in observational cohorts. Aerobic exercise and certain probiotic strains (Lactobacillus and Bifidobacterium species have been studied) have also been reported to lower TMAO in small trials. Experimental compounds that block the bacterial enzyme responsible for producing TMA, such as 3,3-dimethyl-1-butanol, have reduced TMAO and atherosclerotic lesion size in mouse models; these are not FDA-approved therapies and should not be recommended outside of research settings.

The evidence boundary matters here: it is established that diet changes TMAO levels, and plausible that this reflects a real shift in gut microbial metabolism. It is not established that lowering TMAO, by diet or any other means, reduces heart attacks, strokes, or cardiovascular death, because the outcome trials needed to show that have not been done. Clinicians and patients should treat TMAO reduction as a reasonable adjunct to standard cardiovascular risk management (statins when indicated, blood pressure control, smoking cessation, established dietary patterns like Mediterranean or DASH), not as a replacement for it.

TMAO compared with other cardiovascular biomarkers

TMAO does not replace LDL cholesterol, high-sensitivity CRP, or lipoprotein(a). It captures a different biological axis, the gut-to-vascular pathway, rather than lipid transport or systemic inflammation. Combining TMAO with hs-CRP has been proposed in the literature as a way to refine risk stratification beyond either marker alone, though the specific magnitude of any combined-risk estimate should be checked against the primary source before it is used in patient counseling. Unlike lipoprotein(a), which is largely genetically fixed and currently lacks an approved lowering therapy, TMAO is meaningfully influenced by diet, which is part of why it is discussed as an actionable marker even though the outcome-trial evidence for acting on it is still incomplete.

Repeat testing

For a patient with elevated TMAO starting dietary changes, rechecking at roughly 8 to 12 weeks is a reasonable interval to see whether the intervention moved the number. Once a patient's TMAO is consistently in the low-risk range on sustained dietary changes, annual rechecking is usually sufficient. Patients with CKD stages 4 to 5 should expect persistently elevated TMAO because of impaired renal clearance regardless of diet; in this group, the more useful goal is reducing dietary TMA precursors rather than chasing a specific TMAO number, and cardiovascular risk should be managed with the CKD-specific tools already in use rather than by TMAO alone.

When to seek urgent care instead of ordering a lab test

TMAO is a risk-stratification tool for stable outpatients, not an emergency test. Chest pain, sudden shortness of breath, one-sided weakness, slurred speech, or other stroke or heart attack symptoms need emergency evaluation regardless of any prior TMAO result. A high or low TMAO value does not rule in or rule out an acute cardiac event.

Decision framework: should this patient get a TMAO test?

Use this as a starting point for a conversation with the ordering clinician, not as a substitute for individualized medical judgment.

What is established, what is plausible, and what is not established

Established: TMAO is produced through a gut-bacteria-to-liver pathway from dietary choline, carnitine, and betaine. In multiple observational cohorts, higher plasma TMAO has been associated with increased cardiovascular events and mortality, independent of some traditional risk factors. TMAO rises with reduced kidney function and with higher dietary intake of animal-derived precursors.

Plausible but unproven: That TMAO is directly causal in atherosclerosis and thrombosis in humans, based on mechanistic and animal data. That deliberately lowering TMAO through diet, probiotics, or investigational drugs reduces cardiovascular events in people, rather than simply moving a biomarker.

Not established: A single cross-society consensus reference range for TMAO. Routine TMAO screening for the general population. Any FDA-approved drug indicated specifically to lower TMAO for cardiovascular prevention.